Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...

Schulich Medicine & Dentistry research operations lead Kristy Coleman and professor Dr. Elizabeth Finger (L to R) found intermittent dosing of oxytocin can help improve apathy symptoms in ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Mark Cuban Says If You Want To Get Rich, 'Throw A Hail Mary' And Invest 10% Of Savings In Bitcoin, But You Must Pretend You Already Lost It Charlie Munger Praised Buffett's $20 Billion 'No-Brainer ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.